- Home
- CRT vs MAIA Comparison
CRT vs MAIA Comparison
Compare CRT & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CRT | MAIA |
|---|---|---|
| Founded | 1991 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.5M | 49.3M |
| IPO Year | 1992 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CRT | MAIA |
|---|---|---|
| Price | $8.00 | $1.52 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 28.7K | ★ 923.3K |
| Earning Date | 03-12-2026 | 11-07-2025 |
| Dividend Yield | ★ 9.58% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.74 | N/A |
| Revenue | ★ $5,621,913.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.54 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.07 | $0.87 |
| 52 Week High | $13.31 | $2.74 |
Technical Indicators
Market Signals| Indicator | CRT | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 47.56 | 57.14 |
| Support Level | $7.77 | $1.33 |
| Resistance Level | $8.10 | $1.66 |
| Average True Range (ATR) | 0.29 | 0.14 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 66.24 | 72.64 |
Price Performance
Historical ComparisonAbout CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.